Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0072
UNCHANGED
Streaming Delayed Price
Updated: 3:47 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Revive Therapeutics Ltd
< Previous
1
2
3
4
5
6
7
8
9
Next >
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
↗
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
↗
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
↗
April 03, 2023
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...
Via
Benzinga
Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment
↗
March 28, 2023
Life sciences company Revive Therapeutics Ltd.
Via
Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
↗
February 13, 2023
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
Via
Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
↗
February 06, 2023
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
Via
Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
↗
February 03, 2023
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Via
Benzinga
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
↗
January 17, 2023
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Via
Benzinga
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
↗
January 12, 2023
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.<
Via
Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
↗
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
↗
December 16, 2022
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).
Via
Benzinga
Revive Therapeutics To Raise Up To $5M Via Private Placement
↗
December 01, 2022
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;.
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022
↗
November 30, 2022
Via
Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
November 29, 2022
Via
Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
↗
November 28, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022
↗
November 25, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
↗
November 24, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
↗
November 23, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
↗
November 22, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022
↗
November 21, 2022
Via
Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
↗
November 18, 2022
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
↗
November 17, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
↗
November 16, 2022
Via
Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
November 15, 2022
Via
Benzinga
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
↗
November 10, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05
Via
Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
↗
November 09, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS:
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 8, 2022
↗
November 08, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14
Via
Benzinga
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
↗
November 07, 2022
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
↗
November 03, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27
Via
Benzinga
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
↗
November 02, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
